The research lab of Joseph P. Bidwell, PhD, focuses on the improvement of therapies for restoring bone lost to osteoporosis or other diseases. Investigators in this lab have identified a gene that represses the efficacy of medications used to add new bone to the osteoporotic skeleton. They are using state-of-the-art molecular, cellular and animal-model approaches to design strategies for blocking the action of this gene, including techniques that inhibit the bone inhibitor. The U.S. Department of Defense and Eli Lilly and Company currently funds the ongoing work in this laboratory.
For a full list of Bidwell’s publication history, please find him on PubMed.